ANALYSIS: As Vital Healthcare revives a restructuring scheme, directors of its external manager seem particularly antsy about their independence.
ANALYSIS: There is no shortage of cautionary tales about implementing SAP, but Synlait still managed to screw it up.
ANALYSIS: The NZX is right to back away from its selected candidate as chair, but why did it take so long?
ANALYSIS: Ryman has more questions to answer after the disastrous consequences of its foray into the US debt market.
ANALYSIS: There’s a lot to like about the growth and potential listing of the Punakaiki Fund, as long as investors keep their feet on the ground.
ANALYSIS: More than four years after a clash with shareholder activists the stock exchange hasn’t silenced its critics.
ANALYSIS: The net carbon zero credentials of biomass are questionable, but maybe the power generator has a solution to forestry slash.
ANALYSIS: Shareholders are paying the price for management’s badly judged borrowing.
ANALYSIS: Any benefits from Laybuy’s proposal to exit the ASX are unlikely to accrue to minority shareholders.
OPINION: It has its flaws, but the only tax policy worth discussing so far has come from one of the smallest parties – TOP.
